Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 352 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

for
Recurrent Ovarian High Grade Serous Adenocarcinoma,
Location: Philadelphia PA, Charlottesville VA, Winston-Salem NC,
Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT04633239

Phase1, Recruiting

Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy

for
Ovary Cancer, Endometrial Cancer, Uterine Cancer
Location: Chicago IL
Sponsor: Northwestern University

Sex: Female

Age: 18+

Code: NCT05990426

Recruiting

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

for
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma,
Location: Seattle WA
Sponsor: University of Washington

Sex: All

Age: 0+

Code: NCT06295965

Recruiting

Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)

for
Ovarian Neoplasm, Depressive Symptoms, Quality of Life
Location: Houston TX
Sponsor: Baylor College of Medicine

Sex: Female

Age: 18+

Code: NCT05752448

Recruiting

A Study of DM002 in Patients With Advanced Solid Tumors

for
Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms,
Location: Huntersville NC, Houston TX, Oklahoma City OK,
Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

Sex: All

Age: 18+

Code: NCT06751329

Phase1, Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

for
Mesothelioma, Malignant Mesothelioma (MM),
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT05960773

Phase2, Recruiting

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

for
Ovarian Neoplasms
Location: Montreal
Sponsor: GlaxoSmithKline

Sex: Female

Age: 18+

Code: NCT07286266

Phase3, Recruiting

Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians

for
Ovarian Carcinoma, Psychiatric Disorder
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 18+

Code: NCT07282158

Recruiting

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

for
BRCA1 Mutation, POLD1 Gene Mutation, CDKN2A Mutation,
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 25+

Code: NCT05420064

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

for
Ovarian Neoplasms, Fallopian Tube Neoplasms,
Location: Scarborough ME, Providence RI, Farmington CT,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07213804

Phase3, Recruiting

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

for
Ovarian Neoplasms, Breast Neoplasms,
Location: Boston MA, New York NY, Philadelphia PA, Glen Burnie MD,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07213791

Phase1, Recruiting

Study of How People Make Decisions About Prostate Cancer Risk

for
BRCA1/2, Geneitic Testing
Location: New York NY
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: Male

Age: 45 - 70

Code: NCT07197723

Recruiting

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

for
Ovarian Neoplasms, Breast Neoplasms
Location: Boston MA, Lake Success NY, Morristown NJ, Toronto,
Sponsor: GlaxoSmithKline

Sex: All

Age: 18+

Code: NCT04641247

Phase2, Recruiting

Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy

for
BRCA1 Mutation, BRCA2 Mutation
Location: Durham NC, Chapel Hill NC
Sponsor: Duke University

Sex: Female

Age: 19 - 50

Code: NCT06972719

Recruiting

Prostate Cancer Genetic Risk Evaluation and Screening Study

for
Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation,
Location: Boston MA
Sponsor: Massachusetts General Hospital

Sex: Male

Age: 35 - 70+

Code: NCT05129605

Recruiting

Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors

for
Low Grade Ovarian Serous Adenocarcinoma,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 0+

Code: NCT00488878

Recruiting

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

for
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Location: Philadelphia PA, Pittsburgh PA, Chicago IL, Madison WI,
Sponsor: University of Colorado, Denver

Sex: Female

Age: 18 - 70+

Code: NCT05887609

Phase2, Recruiting

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for
Ovarian Carcinoma
Location: Portland ME, Scarborough ME, Boston MA, Providence RI,
Sponsor: NRG Oncology

Sex: Female

Age: 35 - 50

Code: NCT04251052

Recruiting

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

for
Platinum-Resistant Fallopian Tube Carcinoma,
Location: Scottsdale AZ
Sponsor: Mayo Clinic

Sex: Female

Age: 18+

Code: NCT06483048

Phase1, Recruiting

Genetic Testing Decision Aid

for
Epithelial Ovarian Carcinoma, Pancreas Adenocarcinoma
Location: Danvers MA, Boston MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT05470920

Recruiting